Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Work In Process: 2016-2025

Historic Work In Process for Heron Therapeutics (HRTX) over the last 8 years, with Sep 2025 value amounting to $26.3 million.

  • Heron Therapeutics' Work In Process rose 43.54% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 43.54%. This contributed to the annual value of $27.2 million for FY2024, which is 86.87% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Work In Process is $26.3 million, which was up 0.76% from $26.1 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Work In Process peaked at $29.0 million during Q1 2025, and registered a low of $9.0 million during Q2 2023.
  • For the 3-year period, Heron Therapeutics' Work In Process averaged around $19.7 million, with its median value being $17.9 million (2023).
  • In the last 5 years, Heron Therapeutics' Work In Process spiked by 205.75% in 2021 and then crashed by 55.18% in 2023.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Work In Process stood at $20.9 million in 2021, then decreased by 1.01% to $20.7 million in 2022, then dropped by 29.79% to $14.6 million in 2023, then soared by 86.87% to $27.2 million in 2024, then soared by 43.54% to $26.3 million in 2025.
  • Its last three reported values are $26.3 million in Q3 2025, $26.1 million for Q2 2025, and $29.0 million during Q1 2025.